SS Innovations International (NASDAQ: SSII) has reported record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year, signaling continued strong demand for its SSi Mantra surgical robotic system. The company's first-half revenue reached $25.0 million, up 65.6% from $15.1 million in the first half of 2025, reflecting accelerating commercial traction.
The company's growth is driven primarily by system installations, which rose 30.4% to 30 systems during the quarter, bringing the total installed base to 224 SSi Mantra systems across 12 countries. Cumulative surgeries performed on the platform reached 12,272, highlighting its growing clinical utilization. Gross profit for the second quarter increased 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% year-over-year, partly due to investments in scaling operations. For the first half, gross profit jumped 77.5% to $12.4 million, with margin improvement to an undisclosed level.
These results underscore the company's strategic positioning in the surgical robotics market, which is increasingly competitive with established players. SS Innovations' focus on affordability and telesurgery capabilities differentiates the SSi Mantra platform, potentially expanding access to robotic surgery in emerging markets. The company's telesurgery achievements are extending the clinical profile of SSi Mantra, while system installations remain the primary commercial growth driver.
Looking ahead, regulatory milestones could serve as significant catalysts. The company is targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. These approvals would open access to the U.S. and European markets, which represent substantial opportunities for growth. The company's progress in these areas will be closely watched by investors and healthcare providers.
The record revenue and installation numbers reflect a broader trend of increasing adoption of robotic-assisted surgery globally. As hospitals seek to improve patient outcomes and operational efficiency, platforms like SSi Mantra offer a compelling value proposition. The company's ability to sustain its growth trajectory will depend on its execution of regulatory strategies and continued expansion of its installed base.
For more information on SS Innovations International and its recent developments, visit the company's newsroom at https://ibn.fm/SSII.
